Which has preferable earnings & valuation, ARVN or HRMY?

Harmony Biosciences has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 1.99 -$80.80M -$3.32 N/A Harmony Biosciences $868.45M 2.37 $158.69M $2.48 14.33

Is ARVN or HRMY more profitable?

Harmony Biosciences has a net margin of 16.20% compared to Arvinas' net margin of -247.54%. Harmony Biosciences' return on equity of 17.19% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% Harmony Biosciences 16.20% 17.19% 11.99%

Which has better valuation & earnings, ARVN or OCUL?

Arvinas has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 1.99 -$80.80M -$3.32 N/A Ocular Therapeutix $51.95M 41.64 -$265.94M -$1.46 N/A

Does the media favor ARVN or OCUL?

In the previous week, Ocular Therapeutix had 2 more articles in the media than Arvinas. MarketBeat recorded 4 mentions for Ocular Therapeutix and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Ocular Therapeutix's score of 0.86 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARVN or PVLA?

In the previous week, Palvella Therapeutics had 2 more articles in the media than Arvinas. MarketBeat recorded 4 mentions for Palvella Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Palvella Therapeutics' score of 1.45 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ARVN or ADMA?

ADMA Biologics has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 1.99 -$80.80M -$3.32 N/A ADMA Biologics $510.17M 4.08 $146.93M $0.68 13.19

Is ARVN or ADMA more profitable?

ADMA Biologics has a net margin of 32.43% compared to Arvinas' net margin of -247.54%. ADMA Biologics' return on equity of 39.98% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% ADMA Biologics 32.43% 39.98% 28.08%

Does the media favor ARVN or ADMA?

In the previous week, ADMA Biologics had 37 more articles in the media than Arvinas. MarketBeat recorded 39 mentions for ADMA Biologics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat ADMA Biologics' score of 0.12 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 35 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GLUE or ARVN?

In the previous week, Monte Rosa Therapeutics had 4 more articles in the media than Arvinas. MarketBeat recorded 6 mentions for Monte Rosa Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Monte Rosa Therapeutics' score of 0.07 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Arvinas (ARVN) Competitors

$8.10 -0.17 (-2.06%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$7.95 -0.15 (-1.84%)

As of 04:12 AM Eastern

Compare

ARVN vs. HRMY, OCUL, PVLA, ADMA, and GLUE

Should you buy Arvinas stock or one of its competitors? MarketBeat compares Arvinas with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arvinas include Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA), ADMA Biologics (ADMA), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

How does Arvinas compare to Harmony Biosciences?

Arvinas (NASDAQ:ARVN) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Harmony Biosciences has a net margin of 16.20% compared to Arvinas' net margin of -247.54%. Harmony Biosciences' return on equity of 17.19% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Harmony Biosciences	16.20%	17.19%	11.99%

In the previous week, Arvinas had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.91 beat Arvinas' score of 1.89 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Arvinas	Very Positive
Harmony Biosciences	Very Positive

Harmony Biosciences has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A
Harmony Biosciences	$868.45M	2.37	$158.69M	$2.48	14.33

Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Arvinas presently has a consensus price target of $15.42, indicating a potential upside of 90.33%. Harmony Biosciences has a consensus price target of $42.50, indicating a potential upside of 19.58%. Given Arvinas' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Harmony Biosciences beats Arvinas on 10 of the 16 factors compared between the two stocks.

How does Arvinas compare to Ocular Therapeutix?

Arvinas (NASDAQ:ARVN) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Arvinas has a net margin of -247.54% compared to Ocular Therapeutix's net margin of -558.24%. Arvinas' return on equity of -44.38% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Ocular Therapeutix had 2 more articles in the media than Arvinas. MarketBeat recorded 4 mentions for Ocular Therapeutix and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Ocular Therapeutix's score of 0.86 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arvinas currently has a consensus target price of $15.42, indicating a potential upside of 90.33%. Ocular Therapeutix has a consensus target price of $25.11, indicating a potential upside of 154.16%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Arvinas has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Summary

Arvinas beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does Arvinas compare to Palvella Therapeutics?

Arvinas (NASDAQ:ARVN) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Arvinas has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the broader market.

Palvella Therapeutics has lower revenue, but higher earnings than Arvinas. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A
Palvella Therapeutics	$42.81M	48.92	-$41.72M	-$4.17	N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Palvella Therapeutics had 2 more articles in the media than Arvinas. MarketBeat recorded 4 mentions for Palvella Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Palvella Therapeutics' score of 1.45 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas presently has a consensus price target of $15.42, suggesting a potential upside of 90.33%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 36.64%. Given Arvinas' higher probable upside, equities analysts plainly believe Arvinas is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Summary

Arvinas beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arvinas compare to ADMA Biologics?

Arvinas (NASDAQ:ARVN) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Arvinas presently has a consensus price target of $15.42, indicating a potential upside of 90.33%. ADMA Biologics has a consensus price target of $19.67, indicating a potential upside of 119.25%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ADMA Biologics has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A
ADMA Biologics	$510.17M	4.08	$146.93M	$0.68	13.19

ADMA Biologics has a net margin of 32.43% compared to Arvinas' net margin of -247.54%. ADMA Biologics' return on equity of 39.98% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
ADMA Biologics	32.43%	39.98%	28.08%

Arvinas has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, ADMA Biologics had 37 more articles in the media than Arvinas. MarketBeat recorded 39 mentions for ADMA Biologics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat ADMA Biologics' score of 0.12 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	35 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats Arvinas on 11 of the 16 factors compared between the two stocks.

How does Arvinas compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Arvinas has a net margin of -247.54% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Arvinas	-247.54%	-44.38%	-28.38%

Monte Rosa Therapeutics has higher earnings, but lower revenue than Arvinas. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	15.01	-$38.63M	-$1.48	N/A
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A

In the previous week, Monte Rosa Therapeutics had 4 more articles in the media than Arvinas. MarketBeat recorded 6 mentions for Monte Rosa Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Monte Rosa Therapeutics' score of 0.07 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Monte Rosa Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Monte Rosa Therapeutics presently has a consensus target price of $33.33, suggesting a potential upside of 51.65%. Arvinas has a consensus target price of $15.42, suggesting a potential upside of 90.33%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Arvinas beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARVN vs. The Competition

Export

Metric	Arvinas	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$533.59M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-2.44	20.85	27.12	24.26
Price / Sales	1.99	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.20	8.49	10.89	6.29
Net Income	-$80.80M	$23.83M	$3.58B	$330.66M
7 Day Performance	-5.70%	-3.56%	-2.11%	-1.35%
1 Month Performance	6.86%	6.31%	3.28%	-0.64%
1 Year Performance	2.92%	48.30%	26.33%	19.08%

Arvinas Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARVN Arvinas	3.5427 of 5 stars	$8.10 -2.1%	$15.42 +90.3%	+4.0%	$533.59M	$262.60M	N/A	420	News Coverage Gap Up
HRMY Harmony Biosciences	4.7556 of 5 stars	$37.01 -0.7%	$41.44 +12.0%	+4.5%	$2.16B	$868.45M	15.02	200	Positive News
OCUL Ocular Therapeutix	3.2148 of 5 stars	$9.66 +0.2%	$25.11 +159.9%	-10.4%	$2.11B	$51.95M	N/A	230
PVLA Palvella Therapeutics	2.697 of 5 stars	$140.31 -4.4%	$199.53 +42.2%	+451.9%	$2.10B	$42.81M	N/A	N/A	News Coverage
ADMA ADMA Biologics	4.4711 of 5 stars	$9.16 +2.3%	$19.67 +114.7%	-51.5%	$2.07B	$510.17M	13.47	530	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Competitors

ARVN vs. HRMY, OCUL, PVLA, ADMA, and GLUE

How does Arvinas compare to Harmony Biosciences?

Summary

How does Arvinas compare to Ocular Therapeutix?

Summary

How does Arvinas compare to Palvella Therapeutics?

Summary

How does Arvinas compare to ADMA Biologics?

Summary

How does Arvinas compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arvinas (ARVN) Competitors

ARVN vs. HRMY, OCUL, PVLA, ADMA, and GLUE

How does Arvinas compare to Harmony Biosciences?

Do institutionals & insiders believe in ARVN or HRMY?

Is ARVN or HRMY more profitable?

Does the media refer more to ARVN or HRMY?

Which has preferable earnings & valuation, ARVN or HRMY?

Which has more volatility & risk, ARVN or HRMY?

Do analysts prefer ARVN or HRMY?

Summary

How does Arvinas compare to Ocular Therapeutix?

Is ARVN or OCUL more profitable?

Does the media favor ARVN or OCUL?

Which has better valuation & earnings, ARVN or OCUL?

Do insiders & institutionals believe in ARVN or OCUL?

Do analysts recommend ARVN or OCUL?

Which has more risk & volatility, ARVN or OCUL?

Summary

How does Arvinas compare to Palvella Therapeutics?

Which has more volatility & risk, ARVN or PVLA?

Which has preferable earnings & valuation, ARVN or PVLA?

Do insiders & institutionals have more ownership in ARVN or PVLA?

Does the media favor ARVN or PVLA?

Do analysts rate ARVN or PVLA?

Is ARVN or PVLA more profitable?

Summary

How does Arvinas compare to ADMA Biologics?

Do analysts recommend ARVN or ADMA?

Which has better valuation and earnings, ARVN or ADMA?

Is ARVN or ADMA more profitable?

Which has more volatility and risk, ARVN or ADMA?

Does the media favor ARVN or ADMA?

Do institutionals & insiders believe in ARVN or ADMA?

Summary

How does Arvinas compare to Monte Rosa Therapeutics?

Is GLUE or ARVN more profitable?

Which has stronger earnings and valuation, GLUE or ARVN?

Does the media refer more to GLUE or ARVN?

Which has more risk and volatility, GLUE or ARVN?

Do institutionals and insiders hold more shares of GLUE or ARVN?

Do analysts rate GLUE or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools